LEUVEN, Belgium, Sept. 9, 2015 (GLOBE NEWSWIRE) — TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today the list of conferences in which it will participate during the second half of 2015.
24-26 September
ISCT Europe 2015 Regional Meeting, Seville, Spain
Presenter: Eduardo Bravo, Chief Executive Officer
Participant: Maria Pascual, Vice President Regulatory Affairs and Corporate Quality
29-30 September
Cell & Gene Therapy Europe 2015, Barcelona, Spain
Presenters: Maria Pascual, Vice President Regulatory Affairs and Corporate Quality; and Mary Carmen Diez, VP Medical Affairs and New Product Commercialisation
3-7 October
28th Annual Congress of the European Society of Intensive Care, Berlin, Germany
Participant: Marie Paule Richard, Chief Medical Officer
7-8 October
European Large & MidCap Event, Paris, France
Participant: Claudia D’Augusta, Chief Financial Officer
7-9 October
Stem Cell Meeting on the Mesa 2015, California, USA
Presenter: Eduardo Bravo, Chief Executive Officer
Participant: Claudia Jimenez, Senior Director Business Development
24-28 October
United European Gastroenterology Week (UEGW), Barcelona, Spain
Participant: Mary Carmen Diez, VP Medical Affairs and New Product Commercialisation
3-5 November
BIO-Europe 2015, Munich, Germany
Participant: Claudia Jimenez, Senior Director Business Development
9-10 November
KBC Securities Biotech & Healthcare Seminar, New York, USA
Participants: Eduardo Bravo, Chief Executive Officer, and Claudia D’Augusta, Chief Financial Officer
12 November
3rd Annual European Advanced Therapies Investor Day, London, UK
Presenter: Eduardo Bravo, Chief Executive Officer
25 November
Petercam Healthcare CEO Seminar, Brussels, Belgium
Participant: Eduardo Bravo, Chief Executive Officer
For more information
Claudia D’Augusta
Chief Financial Officer
T: +34 91 804 92 64
Ana Pombo
Strategic Planning and IR Manager
T: + 34 91 804 92 64
About TiGenix
TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn’s disease patients. Cx611 has completed a Phase I/II trial in rheumatoid arthritis, as well as a Phase I sepsis challenge trial. Effective as of July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product (AlloCSC-01) is currently in a Phase II clinical trial in acute myocardial infarction (AMI). Coretherapix is planning to initiate the clinical evaluation of AlloCSC-01 in the chronic setting as well and is also involved in the pre-clinical development of a pharmaceutical formulation of growth factors to treat AMI. Finally, TiGenix also developed ChondroCelect, an autologous cell therapy product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA). From June 2014, the marketing and distribution rights of ChondroCelect were exclusively licensed to Sobi for the European Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain).
For more information, please visit www.tigenix.com
Forward-looking information
This document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company’s control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.
HUG#1950635
